Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction

Immunomodulatory therapy for CLAD with ECP or AL was associated with a significant change in FEV1 slope post-treatment compared with pre-treatment slope, with minimal effect on FVC. There was no difference between the 2 therapies in their effect on pulmonary function.